The reduction in cardiovascular risk in REDUCE-IT is due to eicosapentaenoic acid in icosapent ethyl
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
This commentary refers to ‘A possible explanation for the contrasting results of REDUCE-IT vs. STRENGTH: cohort study mimicking trial designs’, by T. Doi et al., https://doi.org/10.1093/eurheartj/ehab555 and the discussion piece ‘Mineral oil and icosapent ethyl may jointly explain the between arm difference of cardiovascular risk in REDUCE-IT’ by T. Doi et al., https://doi.org/10.1093/eurheartj/ehab764. We have read with interest the analysis trying to emulate the results of the REDUCE IT and STRENGTH trials using the Copenhagen observational database.1 We wish to share several concerns with the authors regarding their assumptions. The analysis assumes that lipid profile differences account for treatment and placebo effects when there are potential myriad other intermediate/surrogate markers. It examined relatively small differences in certain biomarkers, but did not factor in the very large change in eicosapentaenoic acid (EPA) levels that occurred in REDUCE-IT. The latter likely explains the bulk of benefit seen in that trial due to downstream effects of EPA that basic scientists are still unravelling.2 Our main concern is that such an analysis attempting to correlate clinical benefits of EPA to changes in selected surrogate biomarkers can miss major causal known or unknown pathways. The recent demonstration of major cardiovascular benefits of SGLT2 inhibitors despite a moderate glucose-lowering effect exemplifies the potential disconnect between selected surrogate biomarkers and outcomes. In addition, the authors regrettably did not have access to changes in lipid and high sensitivity C-reactive protein (hs-CRP) profiles during follow-up in their study, so instead they compared differences in baseline lipid and hs-CRP profiles and correlated them to differences in risk. Unfortunately, this is problematic because there are major confounding differences between patients compared on the basis of their baseline characteristics (in contrast to what happens in a randomized trial where all things are equal at randomization). In addition, the effect of differences in biomarkers on risk is exaggerated because differences in baseline risk reflect lifetime exposure to different levels of LDL, apo B, triglycerides, and hs-CRP up to enrolment, as opposed to short-term changes, as would be seen in a prospective trial. The issue of placebo choice and changes in biomarkers has been thoroughly reviewed by the US FDA, Health Canada, and the European Medicines Agency, who all concluded that any theoretical effect of placebo choice on the 25% risk reduction seen in REDUCE-IT would have been very small.3 In addition, icosapent ethyl has also been studied in two other randomized trials which did not use any placebo and still showed clear benefit—JELIS with a significant 19% reduction in clinical endpoints and CHERRY with a significant benefit on intravascular ultrasound endpoints.4,5 While clinical events are far more important than any biomarker changes, for those who are concerned about such issues, data from PREPARE-IT 1 will provide another opportunity to assess any effects of pharmaceutical grade mineral oil placebo on hs-CRP levels, including with use of a higher loading dose of placebo in that trial. The totality of evidence of randomized clinical trials (with and without use of a placebo), imaging data, observational data, and basic science data all support an important biological and clinical effect of EPA. As the authors themselves state,1 the available data ‘support the European guideline recommendations to consider use of omega-3 fatty acids (icosapent ethyl 2 × 2 g/day) in combination with a statin in high-risk patients with triglyceride levels between 1.5 and 5.6 mmol/L (135–499 mg/dL) despite statin treatment’. Conflict of interest: G.S. discloses the following relationships: research grants: Amarin, Bayer, Sanofi, and Servier; Clinical Trials (Steering committee, CEC, DSMB): Amarin, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Idorsia, Novartis, Pfizer, Sanofi, Servier; consulting or speaking: Amgen, BMS/Myokardia, Novo-Nordisk, Regeneron; and senior associate editor at Circulation. D.L.B. discloses the following relationships—advisory board: Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, Janssen, Level Ex, Medscape Cardiology, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Regado Biosciences; board of directors: Boston VA Research Institute, Society of Cardiovascular Patient Care, TobeSoft; chair: Inaugural Chair, American Heart Association Quality Oversight Committee; data monitoring committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Contego Medical (Chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial,
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This benefit remained significant even considering a slight increase of LDL-C and highsensitivity C-reactive protein due to the effect of mineral oil in the placebo arm.275,276”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [276]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“there has been controversy regarding the use of mineral oil as a comparator within REDUCE-IT, an issue where biomarker and outcome data are limited.[12][13][14]”
From Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy (2022) · cites this paper as [14]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“whereas pharmacologic interventions have proven that lowering of biomarkers such as LDL cholesterol and hsCRP associate with reduced risk”
From Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy (2022) · cites this paper as [14]
Experimental — accuracy not yet measuredIn the citing paper
“the contrapositive conclusion that elevations of these or other biomarkers necessarily increase risk is not proven, nor is the magnitude of any such effect known, even if the effects of the mineral oil comparator used in REDUCE-IT are taken to be causal.[12][13][14]”
From Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy (2022) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317
Self-citationYokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60527-3 · Cited by 2,516
Watanabe, T., Ando, K., Daidoji, H., Otaki, Y., Sugawara, S., Matsui, M., Ikeno, E., Hirono, O., Miyawaki, H., Yashiro, Y., et al. (2017) · Journal of Cardiology · doi:10.1016/j.jjcc.2017.07.007 · Cited by 177
Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies
Olshansky, B., Chung, M. K., Budoff, M. J., Philip, S., Jiao, L., Doyle, Jr., Copland, C., Giaquinto, A., Juliano, R. A., & Bhatt, D. L. (2020) · European Heart Journal Supplements · doi:10.1093/eurheartj/suaa117 · Cited by 103
Self-citationDoi, T., Langsted, A., & Nordestgaard, B. G. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab555 · Cited by 87
Cited by
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Ridker, P. M., Rifai, N., MacFadyen, J., Glynn, R. J., Jiao, L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Tardif, J.-C., et al. (2022) · Circulation · doi:10.1161/circulationaha.122.059410 · Cited by 131
Self-citationChapman, M. J., Zamorano, J. L., & Parhofer, K. G. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108172 · Cited by 67
Omega-3 and cardiovascular prevention – Is this still a choice?
Ruscica, M., Sirtori, C. R., Carugo, S., Calder, P. C., & Corsini, A. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106342 · Cited by 30
Gaba, P., Bhatt, D. L., Mason, R. P., Miller, M. J., Verma, S., Steg, P. G., & Boden, W. E. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.05.067 · Cited by 23
Self-citation
Metadata
- Authors
- Steg, P. G., & Bhatt, D. L.
- Affiliations
- Université de Paris, FACT (French Alliance for Cardiovascular Trials), Assistance Publique-Hôpitaux de Paris and INSERM U1148 , Hôpital Bichat, 46 rue Henri Huchard, Paris 75018, France
- Brigham and Women's Hospital (US)
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-11-03
- Volume
- 42
- Issue
- 47
- Pages
- 4865-4866
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- PMC
- PMC8670779
- OpenAlex
- W3209340813
- Cited by
- 16
- References
- 5
- Citations by year
- 2024: 4 · 2023: 4 · 2022: 6 · 2021: 2
- FWCI
- 2.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- European Heart Journal (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- icosapent ethyl, eicosapentaenoic acid, cardiovascular risk reduction, placebo effect, surrogate markers, lipid profile, high-sensitivity C-reactive protein, mineral oil, omega-3 fatty acids, LDL cholesterol, triglycerides, apolipoprotein B
- MeSH terms
- Heart Disease Risk Factors, Cardiovascular Diseases, Humans, Risk Factors, Eicosapentaenoic Acid, Hypertriglyceridemia, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The reduction in cardiovascular risk in REDUCE-IT is due to eicosapentaenoic acid in icosapent ethyl. https://app.cochat.ai/papers/10.1093/eurheartj/ehab760
- The paper
- Steg, P. G., & Bhatt, D. L. (2021). The reduction in cardiovascular risk in REDUCE-IT is due to eicosapentaenoic acid in icosapent ethyl. European Heart Journal. https://doi.org/10.1093/eurheartj/ehab760
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.